Thanks, Scott, and good afternoon, everyone. Before I dive into our quarterly results, I'd like to highlight the change in presentation of our consolidated adjusted EBITDA that we noted in our release. We have historically excluded Conway extract and ready-to-drink facility start-up costs from our presentation of consolidated adjusted EBITDA. Those start-up costs include two categories. The first category is preproduction costs, which are non-capitalizable costs necessary to place our production and packaging capabilities into commercial production. And the second category is comprised of scale-up operating costs, which represents certain recurring operating costs incurred once the capability is placed into commercial production but before completion of production scale-up. In response to a comment letter from the SEC staff, beginning with these third quarter 2024 results, we no longer exclude the second category, scale-up operating cost, from our presentation of consolidated adjusted EBITDA. As a result, we've revised our year-to-date presentation of our consolidated adjusted EBITDA to account for the impact of scale-up operating costs in prior periods. Because we did not commercialize any of the Conway facility prior to our second quarter of 2024, there's no impact of scale-up operating costs in any prior period other than the second quarter of 2024, in which we incurred $1.2 million of such costs. While we've adjusted our presentation of consolidated adjusted EBITDA, we've not made any changes to our presentation of segment adjusted EBITDA, which is the segment performance measure we use to assess the performance of our operating segments. Segment adjusted EBITDA is defined consistently with consolidated adjusted EBITDA, except that it excludes scale-up operating costs related to the Conway facility. As we continue to commercialize and scale the Conway facility over the next year, we expect the subtotal of our segment adjusted EBITDA will converge with consolidated adjusted EBITDA. With that, I'll now turn to the results for the quarter. On a consolidated basis, net sales for the third quarter were $220.9 million, flat to the third quarter of 2023. Consolidated gross profit for the quarter was up 5.8% over the third quarter of 2023 primarily driven by increased gross profit growth from our SS&T segment. Consolidated adjusted EBITDA for the quarter was $10.3 million and was burdened by almost $4 million of Conway scale-up operating costs related to our multi-serve bottle roasting and grinding and extraction capabilities. This compares to consolidated adjusted EBITDA in the third quarter of 2023 of $11.6 million, which included no Conway scale-up operating costs. For context, historically, we would have added back the $4 million of Conway scale-up operating costs into our third quarter 2024 consolidated net sales, which is a decrease of approximately 7% compared to the third quarter of the prior year. Consistent with prior quarters, we continue to see strong results from our flavors, extracts and ingredients platform with 7% sales growth, while volumes remained under pressure in both core coffee, down 6% from the third quarter of 2023; and single-serve, down 24% from the third quarter of 2023. Despite the drop in net sales, Beverage Solutions segment adjusted EBITDA increased almost 19% to $11.8 million, and our segment adjusted EBITDA margin for Beverage Solutions was up 157 basis points. In our Sustainable Sourcing & Traceability segment, sales, net of intersegment revenues, were $56.9 million in the third quarter of 2024, an increase of 33% compared to the third quarter of 2023, due to a 36% increase in volumes. SS&T segment adjusted EBITDA for the quarter was $2.5 million compared to segment adjusted EBITDA of $1.7 million in the third quarter of 2023. Moving on to capital expenditures, during the third quarter, we deployed approximately $36 million of CapEx primarily related to our Conway extract and RTD facility. Through the end of the third quarter, we spent approximately $275 million of the anticipated $350 million on our Conway facility. We expect to spend approximately $30 million in the fourth quarter of 2024 and the balance in the first half of 2025. We also plan to spend an additional $20 million in capital expenditures in Conway to install a second RTD can line, which will put into service in the second half of 2025. At quarter end, we had approximately $90 million of consolidated unrestricted cash and undrawn revolving credit commitments, and our leverage continues to be in line with our expectations. As previously reported on September 30, we completed our warrant tender offer, exchanging all of our private placement warrants and over 97% of our public warrants, issuing 5.4 million common shares. In connection with the exchange offer, we obtained consent from the requisite number of warrant holders to amend the warrant agreement that allowed the company to force exchange any warrants that remained outstanding after the closing of the exchange offers. On October 16, we exchanged the remaining outstanding public warrants by issuing approximately 100,000 common shares. As a result, there are no remaining warrants outstanding and the public warrants have been delisted. Turning to our guidance. The change in presentation of our consolidated adjusted EBITDA noted in our release and described earlier on the call also necessitates a change in the presentation of our 2024 and 2025 consolidated adjusted EBITDA guidance. With that in mind, we expect to report $50 million of consolidated adjusted EBITDA in fiscal year 2024 under our new presentation. This includes $10 million of scale-up operating costs associated with the Conway facility. This expectation correlates with the low end of our previously announced range. The big drivers of growth that underpinned our original 2024 guidance were continued sales growth in flavors, extracts and ingredients; strength in single-serve cup volumes being delivered on a platform that now has all the equipment necessary to efficiently produce the volumes; and the material scale-up of sales of RTD cans and glass bottles from our Conway facility in the third and fourth quarter of 2024. While flavors, extracts and ingredients had a big year, the challenging macroeconomic environment for the consumer has negatively impacted our single-serve cup volumes and the sales ramp of our extracts and RTD products out of our Conway facility, leading us to the low end of our original 2024 guidance. While we still have to complete our 2025 budget work, preliminarily for fiscal year 2025, we expect to generate consolidated adjusted EBITDA between $80 million and $100 million under our new presentation. This includes approximately $10 million to $15 million of scale-up operating costs associated with the Conway facility. The year-over-year growth and the variability within the 2025 guidance is driven by volume growth in the company's core coffee business from new retail customers, many of whom were onboarded in the back half of 2024; new volume commitments from existing single-serve customers and our expectation for new single-serve customer wins in 2025; the full year benefit of expense savings from our cost reduction and facility consolidation efforts; and the rapid scale-up of our RTD can volumes beginning in the first quarter of 2025 and continuing throughout 2025; and the launch of our RTD glass products in the third quarter of 2025. We will update this guidance as part of our fourth quarter call. With that, I'll turn the call back over to Scott for some closing remarks.